Bringing Retinal Health into focus
Therapeutics for Dry Age-Related Macular Degeneration
Visgenx is developing therapeutics based on increasing expression of a gene known as ELOVL2 which has been shown to regulate aging in the retina and other tissues. Our lead indication is Dry Age-Related Macular Degeneration (Dry AMD).
Resulting in loss of photoreceptor cells and visual acuity
Such as driving, cooking, reading, and facial recognition
There are no approved therapies
We believe dysregulation of lipid (fatty acid) bio-synthesis resulting from declining expression of a gene known as ELOVL2 underlies Dry Macular Degeneration.
Innovation in Focus.
We are scientists, entrepreneurs and drug developers with a goal to develop ELOVL2 based therapeutics to slow or halt aging-related disorders.
Visgenx in Focus.
Our goal is to develop therapeutics that slow or halt cellular senescense in macular degeneration and other age-related disorders by “turning back the clock” to a more youthful level of ELOVL2 expression.